Growth Recovery Among HIV-Infected Children Randomized to Lopinavir/Ritonavir or NNRTI-Based Antiretroviral Therapy

Simple item page
dc.contributor.authorAchan, Jane
dc.contributor.authorKakuru, Abel
dc.contributor.authorIkilezi, Gloria
dc.contributor.authorMwangwa, Florence
dc.contributor.authorCharlebois, Edwin
dc.contributor.authorYoung, Sera
dc.contributor.authorHavlir, Diane
dc.contributor.authorKamya, Moses
dc.contributor.authorRuel, Theodore
dc.date.accessioned2022-08-24T20:24:31Z
dc.date.available2022-08-24T20:24:31Z
dc.date.issued2016
dc.description.abstractDiminished growth is highly prevalent among HIV-infected children and might be improved by antiretroviral therapy (ART). We examined growth recovery in a rural Ugandan cohort of HIV-infected children randomized to lopinavir/ritonavir or non-nucleoside-reverse-transcription-inhibitor-based ART. HIV-infected children 2 months to 6 years of age were randomized to Lopinavir/ritonavir- or non-nucleoside-reverse-transcription-inhibitor-based ART. Changes in weight-for-age (WAZ), height-for-age (HAZ), and weight-for-height (WHZ) Z-scores for 24 months were evaluated using generalized linear repeated-measures models. Recovery from being underweight (WAZ<−2), stunted (HAZ<−2) and wasted (WHZ<−2) to Z-scores > −2 was also compared by arm using Kaplan-Meier survival and Cox proportional hazard modeling. A total of 129 children with median age of 3 years initiated therapy; 64 received Lopinavir/ritonavir-based and 65 non-nucleoside-reverse-transcription-inhibitor-based ART (nevirapine: 36 and efavirenz: 29). The median (IQR) difference in growth measures between baseline and 24 months for Lopinavir/ritonavir (n= 45) vs. non-nucleoside-reverse-transcription-inhibitor-based therapy (n=40) were as follows, WAZ: 0.47 (0.10, 1.62) vs. 0.53 (0.03, 1.14) (p=0.59) and HAZ: median 1.55 (0.78, 1.86) vs. 1.19 (0.62, 1.65) (p=0.23), respectively. ART regimen was not predictive of change in WAZ (beta: −0.02, 95%CI: −0.25, 0.20) or HAZ (beta: 0.05, 95%CI: −0.10, 0.19). Presence of confirmed virologic failure was not associated with growth. Most ART-naive children experienced recovery of both WAZ and HAZ over the 24 months following ART-initiation, with no significant difference between those receiving Lopinavir/ritonavir vs. non-nucleoside-reverse-transcriptase-inhibitor-based ART. However, the persistence of median Z-scores below zero underscores the need for additional strategies to improve growth outcomes in HIV+ African children.en_US
dc.identifier.citationAchan, J., Kakuru, A., Ikilezi, G., Mwangwa, F., Plenty, A., Charlebois, E., ... & Ruel, T. (2016). Growth recovery among HIV-infected children randomized to lopinavir/ritonavir or NNRTI-based antiretroviral therapy. The Pediatric infectious disease journal, 35(12), 1329.https://doi.org/10.1097%2FINF.0000000000001318en_US
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/4412
dc.language.isoenen_US
dc.publisherThe Pediatric infectious disease journalen_US
dc.subjectGrowth recovery, HIV infection, children, antiretroviral drugsen_US
dc.titleGrowth Recovery Among HIV-Infected Children Randomized to Lopinavir/Ritonavir or NNRTI-Based Antiretroviral Therapyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Growth Recovery Among HIV-Infected Children Randomized to LopinavirRitonavir or NNRTI-Based Antiretroviral Therapy.pdf
Size:
221.21 KB
Format:
Adobe Portable Document Format
Description:
Growth Recovery Among HIV-Infected Children Randomized to Lopinavir/Ritonavir or NNRTI-Based Antiretroviral Therapy
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences